Adnkronos Rome, October 15 (Adnkronos Salute) – "This is a tangible, concrete, and important result. CFBox is an innovative and simplified product, achieved in a very short timeframe, as part of funding from the National Center for the Development of Gene Therapies and RNA Drugs. Furthermore, it represents the result of collaboration between the company and a public institution, specifically the Bambino Gesù Children's Hospital Research Institute."
This was stated by Elena Quagliato, head of operational coordination at the National Center for the Development of Gene Therapies and RNA Drugs, today in Rubbiano (Parma), at the presentation of CFBox – the world's first fully automated and customizable isolator for the production of gene and cell therapies (ATMPs) – developed through a collaboration between the PBL company and the Bambino Gesù Children's Hospital (OPBG) thanks to funding of over €3,8 million from the National Research Program (NRRP) by the National Center for RNA and Gene Therapy Research.
"The National Center," Quagliato adds, "has worked tirelessly over the past two years to achieve concrete and tangible results. We are continuing to complete the PNRR, but we are looking beyond. We want these innovations to bear fruit and to continue collaborating together, combining the best Italian expertise in gene therapy and RNA therapeutics production. We want to look beyond PNRR funding," he emphasizes. "We are seeking additional funding and investors, looking at other companies that may be interested in the Center. The goal is to provide products that can be used by the national healthcare system. From a sustainability and efficacy perspective," he concludes, "we want to develop personalized medicine that focuses on the individual."